

MEDICAL POLICY

POLICY TITLE	DENGVAXIA
POLICY NUMBER	MP 2.381

Effective Date:	7/1/2023
-----------------	----------

- | | | |
|----------------------------------|------------------------------------|--|
| POLICY RATIONALE | PRODUCT VARIATIONS | DESCRIPTION BACKGROUND |
| DISCLAIMER | DEFINITIONS | BENEFIT VARIATIONS |
| POLICY HISTORY | CODING INFORMATION | REFERENCES |

I. POLICY

Dengvaxia® may be **medically necessary** when all of the following are met:

1. Members 9 through 16 years of age **and**
2. Laboratory-confirmed previous dengue infection **and**
3. Living in an endemic area

All other indications are considered **investigational**.

Policy Guidelines

See CDC guidelines for recommended laboratory testing

<https://www.cdc.gov/dengue/vaccine/hcp/testing.html>

See CDC for Dengue-Endemic Areas

<https://www.cdc.gov/dengue/vaccine/hcp/index.html>

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross please see additional information below, and subject to benefit variations as discussed in Section VI below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies> .

III. DESCRIPTION/BACKGROUND

[TOP](#)

According to the Center for Disease Control and Prevention (CDC), the Dengue virus is spread through the bite of an infected mosquito. Dengue is often the leading cause of illness in those areas at high risk. Dengue is caused by one of four related viruses, leaving a person vulnerable to being infected as many as four times in a lifetime. Symptoms can include nausea, vomiting, rash, aches, and fever and typically last 2-7 days. There is no specific treatment for dengue.

MEDICAL POLICY

POLICY TITLE	DENG VAXIA
POLICY NUMBER	MP 2.381

According to the CDC, Prevention is by avoiding mosquito bites by using insect repellent or wearing clothing that covers arms and legs. There is a dengue vaccine recommended for U.S. territories of American Samoa, Puerto Rico, the U.S. Virgin Islands, and freely associated states which include the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau. Dengvaxia is the only dengue vaccine approved by the U.S. Food and Drug Administration and recommended for routine use by the Advisory Committee On Immunization Practices. The second dengue virus infection is the most likely to cause hospitalization or severe disease. This vaccine is not to be given to an individual without laboratory evidence of previous virus infection.

Per the United States Food and Drug Administration package insert, Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1,2,3, and 4. Dengvaxia is approved for those individuals 9 through 16 years of age with laboratory-confirmed previous infection and living in an endemic area. Dengvaxia is not approved for use in individuals not previously infected by the dengue virus serotype or for whom this information is unknown. Those not previously infected are at increased risk of severe dengue disease when vaccinated and subsequently infected with the dengue virus. The safety and effectiveness of Dengvaxia have not been established for those living in dengue nonendemic areas who travel to dengue-endemic areas.

IV. RATIONALE

[TOP](#)

This policy was created to ensure the safe and clinically appropriate use of the Dengvaxia vaccine.

V. DEFINITIONS/BACKGROUND

[TOP](#)

Vaccine: A preparation that is used to stimulate the body’s immune response against diseases. Vaccines are usually administered through needle injections, but some can be administered by mouth or sprayed into the nose.

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member’s health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits, and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member’s health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital Blue Cross’s medical policies are developed to assist in administering a member’s benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any

MEDICAL POLICY

POLICY TITLE	DENGVAXIA
POLICY NUMBER	MP 2.381

medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member’s benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member’s plan of benefits, please contact Capital Blue Cross’ Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement. The codes need to be in numerical order.

Covered when medically necessary:

Procedure Codes							
90587							

IX. REFERENCES

[TOP](#)

1. *Dengue. Centers for Disease Control and Prevention website. Accessed March 28, 2023 .*
2. *Dengue For Healthcare Providers: A Dengue Vaccine can Protect Your Patients. Centers for Disease Control and Prevention. Accessed March 28, 2023.*
3. *Dengue, Vaccine Eligibility & Recommendations. Centers for Disease Control and Prevention Accessed March 28, 2023.*
4. *Dengue, Laboratory Testing Requirements for Vaccination with Dengvaxia Dengue Vaccine. Centers for Disease Control and Prevention. Accessed March 28, 2023*
5. *Immunization: The Basics. Center for Disease Control and Prevention. Accessed March 28, 2023.*
6. *United States Food and Drug Administration. Dengvaxia FDA package Insert. Accessed March 28, 2023.*
7. *Advisory Committee on Immunization Practices. Dengue for healthcare providers: Prevention. Accessed March,28, 2023*
8. *World Health Organization. Dengue and severe dengue Fact Sheet. Accessed March 28, 2023*

MEDICAL POLICY

POLICY TITLE	DENGVAXIA
POLICY NUMBER	MP 2.381

X. POLICY HISTORY

[TOP](#)

MP 2.381	6/10/2022 New policy.
	3/28/2023 Consensus. Clarifying investigational statement added, no change to intent. References updated. Coding reviews.

[Top](#)

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company[®], Capital Advantage Assurance Company[®] and Keystone Health Plan[®] Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.